Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Advances in Hematology"
DOI: 10.1177/20406207221116577
Abstract: Bruton’s tyrosine kinase (BTK) inhibitors have dramatically changed the treatment of newly diagnosed and relapsed/refractory chronic lymphocytic leukemia (CLL). Ibrutinib, acalabrutinib, and zanubrutinib are Food and Drug Administration (FDA)-approved BTK inhibitors that have all demonstrated… read more here.
Keywords: btk inhibitor; optimal btk; selecting optimal; cll ... See more keywords